PennVax
B
A
Phase 1b Partially Randomized Pilot Study Intended
to Evaluate the Safety and Immunological Effects of
HIV-1DNA Immunization (PennVax-B) With or Without
Co-administration of constructs Containing DNA Encoding
For the Expression of Either IL-12 or IL-15 In HIV
Infected Individuals
Purpose of this Study: :
To determine the safety of HIV-1 DNA constructs (PennVax-B)
and to determine the optimal doses of IL-12 and IL-15
adjuvant constructs when given with PennVax-B
Requirements to Enter Study:
- CD4 > 400, HIV < 75, on stable regimen
Treatment: PennVax-B, IL-12,
IL-15
Duration of Study: 48 Weeks
For
more information contact:
Study
Contacts
Kathryn
Maffei , RN (215) 349-8092
